JP5087171B2 - 5−ヒドロキシトリプタミン−6リガンドとしての1−(アリールスルホニル)−4−(ピペラジン−1−イル)−1h−ベンズイミダゾール類 - Google Patents

5−ヒドロキシトリプタミン−6リガンドとしての1−(アリールスルホニル)−4−(ピペラジン−1−イル)−1h−ベンズイミダゾール類 Download PDF

Info

Publication number
JP5087171B2
JP5087171B2 JP2011536412A JP2011536412A JP5087171B2 JP 5087171 B2 JP5087171 B2 JP 5087171B2 JP 2011536412 A JP2011536412 A JP 2011536412A JP 2011536412 A JP2011536412 A JP 2011536412A JP 5087171 B2 JP5087171 B2 JP 5087171B2
Authority
JP
Japan
Prior art keywords
benzimidazole
alkyl
compound
sulfonyl
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011536412A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508275A (ja
JP2012508275A5 (cg-RX-API-DMAC7.html
Inventor
アンドレイ,パトリック・エム
ヘイダー,サイモン・エヌ
ロビショード,アルバート・ジェイ
ユン,ヒードン
Original Assignee
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5087171(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ワイス・エルエルシー filed Critical ワイス・エルエルシー
Publication of JP2012508275A publication Critical patent/JP2012508275A/ja
Publication of JP2012508275A5 publication Critical patent/JP2012508275A5/ja
Application granted granted Critical
Publication of JP5087171B2 publication Critical patent/JP5087171B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011536412A 2008-11-11 2009-11-10 5−ヒドロキシトリプタミン−6リガンドとしての1−(アリールスルホニル)−4−(ピペラジン−1−イル)−1h−ベンズイミダゾール類 Expired - Fee Related JP5087171B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
US61/113,296 2008-11-11
PCT/US2009/063816 WO2010056644A1 (en) 2008-11-11 2009-11-10 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS

Publications (3)

Publication Number Publication Date
JP2012508275A JP2012508275A (ja) 2012-04-05
JP2012508275A5 JP2012508275A5 (cg-RX-API-DMAC7.html) 2012-07-19
JP5087171B2 true JP5087171B2 (ja) 2012-11-28

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536412A Expired - Fee Related JP5087171B2 (ja) 2008-11-11 2009-11-10 5−ヒドロキシトリプタミン−6リガンドとしての1−(アリールスルホニル)−4−(ピペラジン−1−イル)−1h−ベンズイミダゾール類

Country Status (41)

Country Link
US (1) US8063053B2 (cg-RX-API-DMAC7.html)
EP (1) EP2285784B1 (cg-RX-API-DMAC7.html)
JP (1) JP5087171B2 (cg-RX-API-DMAC7.html)
KR (1) KR101323417B1 (cg-RX-API-DMAC7.html)
CN (1) CN102209713B (cg-RX-API-DMAC7.html)
AP (1) AP2814A (cg-RX-API-DMAC7.html)
AR (1) AR074325A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009314221B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0920682A2 (cg-RX-API-DMAC7.html)
CA (1) CA2740262C (cg-RX-API-DMAC7.html)
CL (1) CL2011001050A1 (cg-RX-API-DMAC7.html)
CO (1) CO6440548A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110247A (cg-RX-API-DMAC7.html)
CU (1) CU24020B1 (cg-RX-API-DMAC7.html)
CY (1) CY1113025T1 (cg-RX-API-DMAC7.html)
DK (1) DK2285784T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2011000130A (cg-RX-API-DMAC7.html)
EA (1) EA018369B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011045A (cg-RX-API-DMAC7.html)
ES (1) ES2389694T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20135805B (cg-RX-API-DMAC7.html)
HR (1) HRP20120561T1 (cg-RX-API-DMAC7.html)
IL (1) IL212213A0 (cg-RX-API-DMAC7.html)
MA (1) MA32788B1 (cg-RX-API-DMAC7.html)
ME (1) ME01129B (cg-RX-API-DMAC7.html)
MX (1) MX2011004996A (cg-RX-API-DMAC7.html)
MY (1) MY156324A (cg-RX-API-DMAC7.html)
NI (1) NI201100093A (cg-RX-API-DMAC7.html)
NZ (1) NZ592563A (cg-RX-API-DMAC7.html)
PE (1) PE20120026A1 (cg-RX-API-DMAC7.html)
PL (1) PL2285784T3 (cg-RX-API-DMAC7.html)
PT (1) PT2285784E (cg-RX-API-DMAC7.html)
RS (1) RS52381B (cg-RX-API-DMAC7.html)
SA (1) SA109300673B1 (cg-RX-API-DMAC7.html)
SI (1) SI2285784T1 (cg-RX-API-DMAC7.html)
SV (1) SV2011003902A (cg-RX-API-DMAC7.html)
TN (1) TN2011000203A1 (cg-RX-API-DMAC7.html)
TW (1) TWI481605B (cg-RX-API-DMAC7.html)
UA (1) UA100192C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010056644A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103283B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0515482A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
JP5080256B2 (ja) * 2004-09-20 2012-11-21 ゼノン・ファーマシューティカルズ・インコーポレイテッド 二環式複素環誘導体およびステアロイル−CoAデサチュラーゼ(SCD)のインヒビターとしてのそれらの使用
MX2007003332A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
CN101084212A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
US12398097B2 (en) 2019-07-29 2025-08-26 Vanderbilt University WDR5-MYC inhibitors
CN117242055A (zh) * 2020-04-22 2023-12-15 里科瑞尔姆Ip控股有限责任公司 选择性雌激素受体降解剂的制备

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003400A1 (en) 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
CN1087294C (zh) 1997-07-11 2002-07-10 史密丝克莱恩比彻姆有限公司 新化合物
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DK0930302T3 (da) 1998-01-16 2003-07-21 Hoffmann La Roche Benzosulfonderivater
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
KR100472126B1 (ko) 1998-08-10 2005-03-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 양성자 펌프 억제제의 프로드러그
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
WO2002032863A1 (en) * 2000-10-20 2002-04-25 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
BR0115102B1 (pt) * 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
MXPA03011638A (es) * 2001-06-15 2004-04-02 Hoffmann La Roche Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5-ht6受体亲和力的4-哌嗪基吲哚衍生物
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
EP1556140A4 (en) 2002-10-15 2006-04-19 Synta Pharmaceuticals Corp NEW COMPOUNDS
CA2563895C (en) 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
WO2006015259A2 (en) 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
DOP2011000130A (es) 2017-04-30
AU2009314221B2 (en) 2012-08-30
NI201100093A (es) 2011-10-31
ES2389694T3 (es) 2012-10-30
CU20110101A7 (es) 2012-01-31
EA018369B1 (ru) 2013-07-30
JP2012508275A (ja) 2012-04-05
EP2285784A1 (en) 2011-02-23
CA2740262A1 (en) 2010-05-20
CN102209713A (zh) 2011-10-05
CO6440548A2 (es) 2012-05-15
MX2011004996A (es) 2011-05-25
BRPI0920682A2 (pt) 2016-09-27
SA109300673B1 (ar) 2013-05-25
AP2814A (en) 2013-12-31
ME01129B (me) 2013-03-20
DK2285784T3 (da) 2012-07-23
US8063053B2 (en) 2011-11-22
SV2011003902A (es) 2011-07-05
MY156324A (en) 2016-02-15
NZ592563A (en) 2012-10-26
PT2285784E (pt) 2012-09-19
AU2009314221A1 (en) 2010-05-20
CY1113025T1 (el) 2016-04-13
IL212213A0 (en) 2011-06-30
EA201100696A1 (ru) 2011-10-31
CR20110247A (es) 2011-06-24
CU24020B1 (es) 2014-07-30
GEP20135805B (en) 2013-04-10
TN2011000203A1 (fr) 2012-12-17
TWI481605B (zh) 2015-04-21
US20100120779A1 (en) 2010-05-13
WO2010056644A8 (en) 2010-11-18
ECSP11011045A (es) 2011-06-30
RS52381B (sr) 2012-12-31
HK1158647A1 (en) 2012-07-20
UA100192C2 (en) 2012-11-26
KR20110075013A (ko) 2011-07-05
CL2011001050A1 (es) 2011-08-19
HRP20120561T1 (hr) 2012-07-31
MA32788B1 (fr) 2011-11-01
KR101323417B1 (ko) 2013-10-29
PL2285784T3 (pl) 2012-12-31
AR074325A1 (es) 2011-01-05
TW201022247A (en) 2010-06-16
AP2011005664A0 (en) 2011-04-30
PE20120026A1 (es) 2012-02-12
EP2285784B1 (en) 2012-07-04
CA2740262C (en) 2013-05-28
ZA201103283B (en) 2012-01-25
SI2285784T1 (sl) 2012-08-31
WO2010056644A1 (en) 2010-05-20
CN102209713B (zh) 2014-07-02

Similar Documents

Publication Publication Date Title
JP5087171B2 (ja) 5−ヒドロキシトリプタミン−6リガンドとしての1−(アリールスルホニル)−4−(ピペラジン−1−イル)−1h−ベンズイミダゾール類
RU2294932C2 (ru) Новые производные индола со сродством к рецептору 5-ht6
JP2009538910A (ja) 5−ヒドロキシトリプタミン−6リガンドとしての1−スルホニルインダゾリルアミン誘導体および1−スルホニルインダゾリルアミド誘導体
US8546402B2 (en) Chromone derivatives, a process for their preparation and their therapeutic applications
KR20080114688A (ko) 5-히드록시트립타민 수용체에 대한 리간드로서의 술포닐 치환된 1h-인돌
JP2006517966A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのヘテロサイクリル−3−スルホニルアザインドールまたは−アザインダゾール誘導体
JP2006505559A (ja) 5−ht6受容体親和性を持つ4−ピペラジニルベンゼンスルホニルインドール
JP2006522812A (ja) 複素環mchr1アンタゴニスト
JP2006518385A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのヘテロサイクリル−3−スルホニルインダゾール
CZ20022880A3 (cs) Deriváty chinolinu jako alfa 2 antagonisté
CN1878756A (zh) 作为5-羟色胺-6配体的磺酰基四氢-3h-苯并(e)吲哚-8-胺化合物
JP2009533441A (ja) 5‐ヒドロキシトリプタミン‐6リガンドとしての置換ジヒドロ[1,4]オキサジノ[2,3,4‐hi]インダゾール誘導体
MX2008015328A (es) Derivados de benzoxazol y benzotiazol como ligandos de 5-hidroxitriptamina-6.
JP2009504738A (ja) 5−ヒドロキシトリプタミン−6リガンドとしてのアジニル−3−スルホニルインダゾール誘導体
JP2009504739A (ja) 5−ヒドロキシトリプタミン−6リガンドとしての置換−3−スルホニルインダゾール誘導体
HK1158647B (en) 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazo as 5-hydroxytryptamine-6 ligands
US20070099912A1 (en) Pyrrolo[2,3-F] and [3,2-F]Isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands
US20090318470A1 (en) 1-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120528

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20120528

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20120619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120809

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120907

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150914

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees